Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with

...

Eli Lilly and Company (LLY) is a global healthcare company with core products in a number of primary-care pharmaceutical markets. The leading product is Zyprexa, a treatment for schizophrenia and bipolar disorder. The company's other leading drugs include Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Byetta (type-II diabetes), Cialis (erectile dysfunction), Strattera (ADHD), and Alimta (chemotherapy).The company is entering a challenging period, brought about by recent pipeline disappointments, most notably uncertainty surrounding antiplatelet drug Prasugrel. Although we believe the underlying fundamentals of the company remain solid, the recent pipeline setbacks and lack of clarity surrounding prasugrel will likely limit the upside to the stock. We also believe that sales of Zyprexa will begin to decline in 2008 as generic Risperdal eats into market share. We see little movement in the stock until the above issues are addressed. We rate the shares a Hold with ...

Hello Friends!  Thanks so much for stopping by and visiting my blog, Stock Picks Bob’s Advice!  As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website.

One of the strongest stocks in my portfolio the past two months has been Quality Systems (QSII).   After purchasing this at a cost basis of approximately $38.18 just last month on August 8, 2008, the stock has moved sharply higher.  QSII closed today at $44.89, well above my purchase price, but down $(2.15) or (4.57)% on the day.

Earlier today, with the market turning higher after a sell-off, I found myself seeing QSII moving sharply lower, lagging the rest of the portfolio.

Although the fundamentals remain …

Having a “white knight” hanging around to give your company a nice infusion of cash is always a nice incentive to taking a bit of a risk. New market entry is always a bit of a risk, even if you have an established product to enter that market with. Not being 100% sure of how that new market will react – socially and financially - to a new product is always the risk. But if the “white knight” is willing to support in more than just a monetary way, the chances of sizable profit can be increased considerably.

Unigene Labs Inc., a biopharmaceutical company, works to develop and market peptide and other related pharmaceuticals. The company currently has an estimated 55% market share of the prescription nasal congestion marketplace and is entering Phase III trials with a new calcintonin product.

The company has been having moderate successes with its Fortical product, although

...